girentuximab

Home
Ligands
girentuximab

GtoPdb Ligand ID: 7987

Synonyms: cG250 | G250 | Rencarex® (proposed proprietary name) | WX-G250

Comment: Girentuximab is a monoclonal antibody directed against carbonic anhydrase 9 (CA9) [5].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.

No information available.

No information available.

Summary of Clinical Use
An iodinated version of the antibody, ¹²⁴I-girentuximab, can be used as a diagnostic tool to image ccRCC (clear cell renal cell carcinoma). No severe side effects or allergic reactions to this antibody have so far been reported from clinical trials [1,3] (see also clinical trial NCT01762592). In addition, a Phase 3 clinical trial (NCT00087022) assessing girentuximab as a post-operative anti-ccRCC agent for non-metastatic disease has been completed.

Summary of Clinical Use

An iodinated version of the antibody, ¹²⁴I-girentuximab, can be used as a diagnostic tool to image ccRCC (clear cell renal cell carcinoma). No severe side effects or allergic reactions to this antibody have so far been reported from clinical trials [1,3] (see also clinical trial NCT01762592). In addition, a Phase 3 clinical trial (NCT00087022) assessing girentuximab as a post-operative anti-ccRCC agent for non-metastatic disease has been completed.

Mechanism Of Action and Pharmacodynamic Effects
CA9 expression is induced by hypoxia, and is present on the surface of the majority of clear cell renal cell carcinoma (ccRCC) cells and hypoxic non-RCC tumours, but not in normal renal tissue [2,4]. Due to this specific expression of CA9 on primary and metastatic ccRCC tumours, the antigen is an excellent immunotherapeutic target for both localized and advanced disease.

Mechanism Of Action and Pharmacodynamic Effects

CA9 expression is induced by hypoxia, and is present on the surface of the majority of clear cell renal cell carcinoma (ccRCC) cells and hypoxic non-RCC tumours, but not in normal renal tissue [2,4]. Due to this specific expression of CA9 on primary and metastatic ccRCC tumours, the antigen is an excellent immunotherapeutic target for both localized and advanced disease.